Dissemination of a telehealth cardiovascular risk service: The CVRS live protocol.

BACKGROUND: Medical clinics are increasingly hiring clinical pharmacists to improve management of cardiovascular disease (CVD). However, the limited number of clinical pharmacists employed in a clinic may not impact the large number of complex patients needing the services. We have developed a remote telehealth service provided by clinical pharmacists to complement CVD services provided by on-site clinical pharmacists and aid sites without a clinical pharmacist. This cardiovascular risk service (CVRS) has been studied in two NIH-funded trials, however, we identified barriers to optimal intervention implementation. The purpose of this study is to examine how to implement the CVRS into medical offices and see if the intervention will be sustained. METHODS: This is a 5-year, pragmatic, cluster-randomized clinical trial in 13 primary care clinics across the US. We randomized clinics to receive CVRS or usual care and will enroll 325 patient subjects and 288 key stakeholder subjects. We have obtained access to the electronic medical records (EMRs) of all study clinics to recruit subjects and provide the pharmacist intervention. The intervention is staggered so that after 12 months, the usual care sites will receive the intervention for 12 months. Follow-up will be accomplished though medical record abstraction at baseline, 12 months, 24 months, and 36 months. CONCLUSIONS: This study will enroll subjects through 2021 and results will be available in 2024. This study will provide unique information on how the CVRS provided by remote clinical pharmacists can be effectively implemented in medical offices, many of which already employ on-site clinical pharmacists. CLINICAL TRIAL REGISTRATION INFORMATION: NCT03660631: http://clinicaltrials.gov/ct2/show/NCT03660631.

Annotations on Mexico's WISC-IV: a validity study.

This project seeks to provide evidence on the internal structure of the Escala Wechsler de Inteligencia para Niños-IV (EWIN-IV; Wechsler, 2007a ) through a confirmatory factor analysis and intercorrelational study. Also provided is information on the adaptation process and other sources of validity evidence in support of the EWIN-IV norms. The standardization data for the EWIN-IV were used for all analyses. The factor loadings and correlational patterns found on the EWIN-IV are comparable to those seen in the American versions of the test. The proposed factor and scoring structure of the EWIN-IV was supported.

Annotations on the use of the Mexican norms for the WAIS-III.

This article provides crucial information to judge the appropriateness of the Mexican version of the Wechsler Adult Intelligence Scale-Third Edition and recognizes some limitations in both the process of its adaptation to the Mexican population and the norm development process. This is an effort to contribute to the debate initiated by Suen and Greenspan (2008), who argued in court against the use of Mexican norms in a death penalty case, which depended upon establishing the diagnosis of mental retardation. As a part of the defense team, these scholars argued a number of points against the use of the Mexican norms. With input from the lead researcher on the Mexican standardization process, some of the criticisms are addressed, and further information about the norm development process for this test in Mexico is provided in an attempt to be critical about the strengths and weaknesses of the use of existing Mexican norms. Finally, we argue that results from a single test must not be used to make life and death decisions and that test development is a continuous process influenced by culture, language, and indeed by norm-developing procedures and debates.